Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cyclophosphamide + epirubicin + nab-paclitaxel + paclitaxel
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of carboplatin, cyclophosphamide, epirubicin, nab-paclitaxel, and paclitaxel. This combination is primarily used in neoadjuvant settings for triple-negative breast cancer (TNBC). The regimen typically involves sequential administration, such as nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide (EC), or other variations of these agents. Nab-paclitaxel is a solvent-free formulation of paclitaxel with an improved safety profile. Epirubicin is an anthracycline considered equivalent to doxorubicin in breast cancer treatment.
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + cyclophosphamide + epirubicin + nab-paclitaxel + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cyclophosphamide + epirubicin + nab-paclitaxel + paclitaxel.